Wealth Alliance Advisory Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$904K Sell
15,689
-43
-0.3% -$2.47K 0.13% 88
2026
Q1
$954K Buy
15,732
+228
+1% +$13.3K 0.15% 90
2025
Q4
$836K Buy
15,504
+657
+4% +$31.6K 0.14% 91
2025
Q3
$670K Sell
14,847
-2,392
-14% -$112K 0.12% 95
2025
Q2
$798K Buy
17,239
+640
+4% +$31.4K 0.15% 81
2025
Q1
$1.01M Sell
16,599
-670
-4% -$39.1K 0.21% 74
2024
Q4
$977K Sell
17,269
-371
-2% -$20.7K 0.21% 74
2024
Q3
$913K Buy
17,640
+10,831
+159% +$508K 0.19% 82
2024
Q2
$283K Sell
6,809
-485
-7% -$21.7K 0.06% 149
2024
Q1
$396K Sell
7,294
-22
-0.3% -$1.12K 0.09% 128
2023
Q4
$375K Sell
7,316
-282
-4% -$14.8K 0.1% 127
2023
Q3
$441K Buy
7,598
+660
+10% +$40.4K 0.13% 102
2023
Q2
$444K Sell
6,938
-259
-4% -$17.4K 0.16% 98
2023
Q1
$499K Buy
7,197
+100
+1% +$7.05K 0.19% 83
2022
Q4
$511K Sell
7,097
-290
-4% -$21.9K 0.2% 79
2022
Q3
$525K Sell
7,387
-73
-1% -$5.29K 0.23% 70
2022
Q2
$574K Sell
7,460
-47
-0.6% -$3.58K 0.27% 64
2022
Q1
$548K Sell
7,507
-4,004
-35% -$269K 0.24% 69
2021
Q4
$718K Sell
11,511
-2,164
-16% -$127K 0.31% 59
2021
Q3
$809K Sell
13,675
-425
-3% -$28K 0.39% 46
2021
Q2
$942K Buy
14,100
+5
+0% +$326 0.46% 42
2021
Q1
$890K Buy
14,095
+1,529
+12% +$95.1K 0.46% 42
2020
Q4
$779K Buy
12,566
+100
+0.8% +$6.15K 0.42% 44
2020
Q3
$752K Sell
12,466
-768
-6% -$46.2K 0.44% 43
2020
Q2
$778K Sell
13,234
-146
-1% -$8.73K 0.48% 37
2020
Q1
$746K Buy
13,380
+139
+1% +$8.5K 0.58% 36
2019
Q4
$850K Buy
13,241
+1,820
+16% +$104K 0.49% 38
2019
Q3
$589K Buy
11,421
+96
+0.8% +$4.51K 0.37% 48
2019
Q2
$500K Hold
11,325
0.31% 54
2019
Q1
$535K Hold
11,325
0.35% 51
2018
Q4
$589K Hold
11,325
0.44% 45
2018
Q3
$703K Hold
11,325
0.36% 55
2018
Q2
$627K Sell
11,325
-89
-0.8% -$4.81K 0.34% 52
2018
Q1
$722K Buy
11,414
+1,800
+19% +$116K 0.42% 47
2017
Q4
$589K Buy
+9,614
New +$601K 0.53% 46

Other funds holding BMY

Wealth Alliance Advisory Group's BMY Position: Q2 2026 in Review

Wealth Alliance Advisory Group reduced its Bristol-Myers Squibb (BMY) stake by 0.27% in Q2 2026, selling an estimated $2.47K and leaving 15,689 shares worth $904K. The position accounts for 0.13% of the portfolio, ranked #88.

Wealth Alliance Advisory Group first reported a position in BMY in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.01M in Q1 2025. 945 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Wealth Alliance Advisory Group held 15,689 shares of Bristol-Myers Squibb worth $904K as of Q2 2026.
  • Wealth Alliance Advisory Group sold 43 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.47K.
  • Bristol-Myers Squibb made up 0.13% of Wealth Alliance Advisory Group's portfolio in Q2 2026, its #88 holding.
  • Wealth Alliance Advisory Group first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 35 quarters since.
  • Wealth Alliance Advisory Group's Bristol-Myers Squibb position peaked at $1.01M in Q1 2025.
  • 945 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.